|Main uses||Relapsing forms of multiple sclerosis (MS)|
|Side effects||Flushing, abdominal pain, diarrhea, nausea|
|US NLM||Diroximel fumarate|
|Chemical and physical data|
|Molar mass||255.226 g·mol−1|
|3D model (JSmol)|
Diroximel fumarate, sold under the brand name Vumerity, is a medication used to treat relapsing forms of multiple sclerosis (MS). This includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is taken by mouth.
Common side effects include flushing, abdominal pain, diarrhea, and nausea. Other side effects may include anaphylaxis, progressive multifocal leukoencephalopathy, herpes zoster, liver problems, and low lymphocytes. Use in pregnancy may harm the baby. It works after the body converts it into monomethyl fumarate (MMF).
Diroximel fumarate was approved for medical use in the United States in 2019. While it was approved in Europe and the United Kingdom in 2021 it is not yet commercially available. In the United States it costs about 7,900 USD per day as of 2021.
Society and culture
This drug was formulated by Alkermes in collaboration with Biogen.
- "Vumerity- diroximel fumarate capsule". DailyMed. Retrieved 1 February 2021.
- "Diroximel fumarate Pregnancy and Breastfeeding Warnings". Retrieved 26 December 2021.
- "Vumerity · Relapsing remitting multiple sclerosis (MS)". Retrieved 26 December 2021.
- "Vumerity Prices, Coupons and Patient Assistance Programs". Retrieved 26 December 2021.
- Wang Y, Bhargava P (July 2020). "Diroximel fumarate to treat multiple sclerosis". Drugs of Today (Barcelona, Spain : 1998). 56 (7): 431–437. doi:10.1358/dot.2020.56.7.3151521. PMID 32648853.
- Kourakis S, Timpani CA, de Haan JB, Gueven N, Fischer D, Rybalka E (October 2020). "Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?". Pharmaceuticals (Basel, Switzerland). 13 (10): 306. doi:10.3390/ph13100306. PMC 7602023. PMID 33066228.
- "Diroximel fumarate". Drug Information Portal. U.S. National Library of Medicine.